Ranibizumab passes first safety profile for NV-AMD

Ranibizumab has passed the one-year safety profile for neovascular age-related macular degeneration (NV-AMD), claims a recent paper.

Professor Frank G. Holz et al., Department of Ophthalmology, University of Bonn, Germany, retrospectively pooled data from 4444 patients from registries in the Netherlands, Belgium, Germany and Sweden.

The data was assessed for one-year incidence rates for safety events of particular interest. This included key ocular or systemic events that may be related to the injection procedure or vascular endothelial growth factor inhibition, along with treatment exposure.

Of the patients studied, between 70.4% and 84.4% of patients completed the one-year follow up. The most frequent ocular events were retinal pigment epithelial tears and IOP-related events. The most frequent non-ocular events was stroke, but the annual incidence was only a maximum of 0.5%.

Ranibizumab 0.5 mg presented favourable one-year safety profile outcomes for NV-AMD. The five-year LUMINOUS prospective observational study will be conducted to evaluate infrequent but serious events in ‘real-life’ settings.

To read the abstract please visit the

British Journal of Ophthalmology

.